Related Experiment Video
Updated: May 3, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
New antiviral agents for the treatment of hepatitis C: ABT-450
Andres F Carrion1, Julio Gutierrez, Paul Martin
1University of Miami, Miller School of Medicine, Division of Gastroenterology , 1120 NW 14th Street, Suite 310E, Miami, FL 33136 , USA +1 305 243 8644 ; +1 305 243 3762 ; acarrionmonsalve@med.miami.edu.
Introduction:
Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 - 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging.
Areas Covered:
Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented.
Expert Opinion:
Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Subviral Agents

